Research programme: HIV maturation inhibitors - Panacos Pharmaceuticals
Alternative Names: Next-generation HIV maturation inhibitors - Panacos; Third-generation HIV maturation inhibitors - PanacosLatest Information Update: 27 Sep 2019
At a glance
- Originator Panacos Pharmaceuticals Inc
- Class Small molecules
- Mechanism of Action Viral core protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in USA (PO)
- 03 Apr 2009 Programmes for the development of second- and third-generation maturation inhibitors is ongoing in the US
- 14 May 2007 Panacos has extended its medicinal chemistry contract with Evotec into its fourth year